Skip to content

Optimal Protein Supplementation and Early Exercise In Mechanically Ventilated Patients

Attenuation of Sarcopenia Using Optimal Protein Supplementation and Early Exercise In Mechanically Ventilated Patients: A Pilot Randomized Controlled Trial (PIVOT)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05603585
Enrollment
150
Registered
2022-11-02
Start date
2022-09-06
Completion date
2023-09-30
Last updated
2023-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cachexia, Nutritional Deficiency

Brief summary

A Pilot Randomized Controlled Trial (RCT) will be conducted where where mechanically ventilated patients will be randomized to optimal protein (Achieve 80% protein supplementation adequacy with daily titration) versus standard protein feeding. Both groups will receive standard usual early exercise therapy. Specific aim 1: To determine if optimal protein supplementation improves functional outcome of patients as measured by Functional Status Score (FSS) on Day 7. Specific aim 2: To determine if optimal protein supplementation reduces muscle loss of patients at Day 7 as measured by the Rectus Femoris thickness and cross-sectional area (RFCSA) using skeletal muscle ultrasound. Specific aim 3: To determine difference in functional recovery between groups using quality of life (QOL) scores and 6-minute walk distance at 3 months after hospital discharge. The hypothesis is protein inadequacy can be overcome with optimized protein supplementation to reduce muscle loss/sarcopenia and functional impairment in ICU survivors.

Detailed description

This study will be a prospective pilot randomized controlled trial. Collaboration will be between the National University Hospital (Medical, Surgical and Cardiothoracic ICUs), Centre for Healthy Aging, National University Health System (NUHS) and Physical Education & Sports Science, National Institute of Education (NIE). Patients admitted into these ICUs will be screened and those meeting the inclusion criteria will be approached for consent. If the patient is unable to consent, his/her legally acceptable representatives will be approached. This approach is routinely done in ICU studies. As with other ICU studies, potential difficulties in consenting and recruiting patients will be expected. To overcome this, all adult ICU patients at NUH will be included in the current study.

Interventions

DIETARY_SUPPLEMENTOptimal protein supplementation to achieve 80% protein adequacy.

Additional protein required and delivered by adding protein powder and given in bolus feeds

Sponsors

National University of Singapore
CollaboratorOTHER
National University Hospital, Singapore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Masking description

The participants and their legally acceptable representative will not be made known of the experimental arms that the participant is allocated to.

Intervention model description

Eligible patients will be randomly assigned to receive either standard feeding or optimised protein feeding based on random permuted blocks with age (≥65 years or \< 65 years) and ICU site of recruitment as the stratification factors. The primary endpoint is difference in FSS between the two groups at Day 7.

Eligibility

Sex/Gender
ALL
Age
21 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

1. Age 21 years and above. 2. Expected mechanical ventilation duration ≥ 48 hours. 3. Expected to stay in hospital for ≥ 4 days.

Exclusion criteria

1. Pregnant woman. 2. Amputation of either lower limbs. 3. Surgery of lower limb during the current admission. 4. 4\. Any neurological/rheumatologic/orthopaedic/burn/trauma/physiological problem with feeding difficulties during 48h of intubation 5. Wheelchair-bound, walking aids and ADL-dependent. 6. Patient not able to feed by 48 hours AND not given parenteral feeding. 7. Patients on Continuous Renal Replacement Therapy. 8. Sepsis with poor prognosis. 9. Competing trial 10. Moribund within 48hours. 11. COVID-19 patients. 12. Declined to participate the study

Design outcomes

Primary

MeasureTime frameDescription
Functional Status Score for ICU (FSS-ICU)Day 1 of Randomisation; Day 7 of Randomisation; Day of ICU Discharge , approximately 14 days after ICU admissionIt is an ordinal score consisting of 5 activities (namely, Rolling in bed, Supine to Sit Transfer, Sit to Stand Transfer, Sitting Edge of Bed, Walking); each activity is scored from 0 to 7 to a total of 35. A higher score indicates a better functioning. It closely resembles Activities of Daily Living (ADL) and it is possible to even measure the pre-admission score. The FSS-ICU is measured at day 1 upon recruitment and compared to a one week period and to the time of discharge in intensive care to determine functional improvements at these time points.

Secondary

MeasureTime frameDescription
Rectus Femoris Cross-Sectional Area (RFCSA) and anterior thigh and rectus femoris thicknessDay 1 of Randomisation; Day 4 of Randomisation; Day 7 of Randomisation; Day of ICU Discharge , approximately 14 days after ICU admissionRFCSA correlates well with quadriceps strength, measured by B-mode ultrasonography using linear transducer array. Pennation angle will also be calculated. The rectus femoris RFCSA and thigh thickness and pennation angle is measured at day 1 upon recruitment and compared to day 4 and then day 7 of study recruitment to determine changes in muscle loss.
Six-Minute Walk Test (6MWT)3 months post hospital dischargeFeasible standard measure of exercise capacity
Clinical Frailty Index (CFI)Day 1 of Randomisation; Day of ICU Discharge , approximately 14 days after ICU admissionThe CFI scoring is a scale from 1 to 9, 1 being very fit (best outcome) while 9 being terminally ill (worst outcome). The CFI is measured at day 1 upon recruitment and compared to point of ICU discharge to determine changes in frailty.
Blood BiomarkersDay 1 of Randomisation; Day 4 of RandomisationThe following cytokines; IL-6, IL-10, IL-12 and TNF-1α and MCP1, HMGB1 will be analysed via blood test to monitor inflammatory reactions
Indirect calorimetry (IC)Day 1 to Day 7 of Randomisation (daily or till extubation)Gold standard for measurement of energy expenditure (EE)

Countries

Singapore

Contacts

Primary ContactGeetha Kayambu
geetha_kayambu@nuhs.edu.sg6779 5555
Backup ContactLian Ting Wong
lian_ting_wong@nuhs.edu.sg

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026